09:02 : Allos Therapeutics (ALTH) -19.3% premarket after receiving a negative ... -
Allos Therapeutics (ALTH) -19.3% premarket after receiving a negative opinion from European regulators on its Folotyn treatment for patients with peripheral T-cell lymphoma. The company says it plans to submit a request for re-examination ...